Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.41 |
| ▸ | DPP4 | P27487 | 7/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923005 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL744198 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL17760540 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL4531927 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL746205 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL25286686 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL5795993 | 1.00 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL418951 | 0.82 | ATM (0.59) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL16751022 | 0.82 | ATM (0.59) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL17511112 | 0.80 | ATM (0.42) | ATMPIK3CDDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2023076849-A1 | INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-3853226-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11053215-B2 | Heterocyclic compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3197445-B1 | PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA | SALAMA ZOSER B (DE) | 2021-04-28 | — | — | EP | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2020061150-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-10450296-B2 | Heterocyclic compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2019-10-22 | — | — | US | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-10328051-B2 | Proline or proline derivatives for the treatment of dementia | SALAMA ZOSER B (DE) | 2019-06-25 | — | — | US | disclosed |
| US-9920032-B2 | Heterocyclic compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170239215-A1 | PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA | SALAMA ZOSER B (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170096411-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-04-06 | — | — | US | disclosed |
| US-8518952-B2 | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8252912-B2 | Transcriptional repression of sodium-iodide symporter in thyroid carcinoma | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-08-28 | — | — | US | disclosed |
| US-7727530-B2 | Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody | SALAMA ZOSER B | 2010-06-01 | — | — | US | disclosed |
| US-20090191584-A1 | Transcriptional repression of sodium-iodide symporter in thyroid carcinoma | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2009-07-30 | — | — | US | disclosed |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | disclosed |
| US-20050276810-A1 | Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody | SALAMA ZOSER B | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10328051-B2 | Proline or proline derivatives for the treatment of dementia | PSEN2, PSEN1, PRNP | ATM 1940/4885PIK3CD 2963/4885DPP4 120/4885 |
| US-20170239215-A1 | PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA | PSEN2, PSEN1, PRNP | ATM 1940/4885PIK3CD 2963/4885DPP4 120/4885 |
| US-11053215-B2 | Heterocyclic compounds useful as Pim kinase inhibitors | PIM1, PIM2, PIM3 | ATM 333/4885PIK3CD 457/4885DPP4 1092/4885 |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | PREP, PRAP1, VHL | ATM 3665/4885PIK3CD 2695/4885DPP4 270/4885 |
| US-10450296-B2 | Heterocyclic compounds useful as Pim kinase inhibitors | PIM1, PIM2, PIM3 | ATM 333/4885PIK3CD 457/4885DPP4 1092/4885 |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | ATM 444/4885PIK3CD 1035/4885DPP4 3709/4885 |
| US-20170096411-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | ATM 333/4885PIK3CD 457/4885DPP4 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.